Cytogenomic Molecular Inversion Probe Array FFPE Tissue - Products of Conception

Also known as: CMAPFFPE

Clinical Use

Use

This test is used to detect copy number alterations and loss of heterozygosity in formalin-fixed, paraffin-embedded (FFPE) specimens from products of conception. It aids in identifying chromosomal abnormalities such as trisomies, monosomies, and other genomic imbalances that can result in pregnancy loss or congenital abnormalities. Genetic counseling and informed consent are strongly recommended due to the nature of the genetic testing.

Special Instructions

Not provided.

Limitations

This analysis does not provide structural information related to genomic imbalances. Certain alterations like CNVs below the resolution limit, sequence-level variants, low-level mosaicism, balanced chromosomal rearrangements, and genomic imbalance in repetitive regions may not be detected. Additional cytogenetic testing such as chromosome analysis or FISH may be necessary for comprehensive assessment. The assay was developed and characteristics determined by ARUP Laboratories, performed in a CLIA certified laboratory without FDA clearance or approval.

Test Details

Methodology

Microarray

Biomarkers

Cytogenomic MIP Array FFPE

LOINC Codes

Order Codes

57723-9 - Unique bar code # Current sample

Result Turnaround Time

14-21 days

Specimen

Tissue (FFPE)

Volume

Not provided

Minimum Volume

Not provided

Collection Instructions

Transport ten slides, each with 5 µm unstained sections or four 20 µm scrolls or tissue block for FFPE fetal tissue. For FFPE villi, transport one H&E stained slide and ten slides, each with 5 µm unstained sections or tissue block.